Eculizumab improves fatigue in refractory generalized myasthenia gravis

Overview of attention for article published in Quality of Life Research, March 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

policy: 1 policy source
patent: 3 patents
peer_reviews: 1 peer review site

facebook: 1 Facebook page
reddit: 2 Redditors

Readers on

mendeley: 133 Mendeley

So far, Altmetric has seen 3 policy documents that reference this research output.

ravulizumab - Clinical and Pharmacoeconomic Combined Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 22 Apr 2024

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

ravulizumab - Clinical, Pharmacoeconomic and Ethics combined Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 08 Aug 2023

eculizumab - Clinical Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 04 Mar 2020

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.